Nano-microparticles as immune adjuvants: Correlating particle sizes and the resultant immune responses

Expert Review of Vaccines

Volumn 9, Issue 9, 2010, Pages 1095-1107

  Oyewumi, Moses O ^a   Kumar, Amit ^b   Cui, Zhengrong ^b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

adjuvants; immune responses; microparticles; nanoparticles; particle size; vaccine formulation

Indexed keywords

CHITOSAN; IMMUNOLOGICAL ADJUVANT; MACROGOL; NANOPARTICLE; OVALBUMIN; POLYGLACTIN; POLYLACTIC ACID; POLYSTYRENE; POLYVINYL ALCOHOL;

ANTIGEN PRESENTING CELL; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EMULSION; FREEZE DRYING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LIPID VESICLE; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; IMMUNITY, INNATE; MICROSPHERES; NANOPARTICLES; PARTICLE SIZE; VACCINES;

EID: 77956494575     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.89     Document Type: Review

References (104)

1. Davis JP. Experience with hepatitis A and B vaccines. Am. J. Med. 118(10 Suppl. 1), 7-15 (2005).
2. Look M, Bandyopadhyay A, Blum JS, Fahmy TM. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv. Drug Deliv. Rev. 62(4-5), 378-393 (2009).
3. O'Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov. 2(9), 727-735 (2003).
4. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell V W. Vaccine adjuvant systems: enhancing the effcacy of sub-unit protein antigens. Int. J. Pharm. 364(2), 272-280 (2008).
5. Copland MJ, Baird MA, Rades T et al. Liposomal delivery of antigen to human dendritic cells. Vaccine 21(9-10), 883-890 (2003).
6. Schijns V. Immunological concepts for vaccine adjuvant activity. Curr. Opin. Immunol. 12(4), 456-463 (2000).
7. Caputo A, Sparnacci K, Ensoli B, Tondelli L. Functional polymeric nano/microparticles for surface adsorption and delivery of protein and DNA vaccines. Curr. Drug Deliv. 5(4), 230-242 (2008).
8. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 82(5), 488-496 (2004).
9. Chang S, Warner J, Liang L, Fairman J. A novel vaccine adjuvant for recombinant fu antigens. Biologicals 37(3), 141-147 (2009).
10. Singh M, Briones M, Ott G, O'Hagan DT. Cationic microparticles: a potent delivety system for DNA vaccines. Proc. Natl Acad. Sci. USA 97, 811-816 (2000).
11. Kalkanidis M, Pietersz GA, Xiang SD et al. Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity. Methods 40(1), 20-29 (2006).
12. Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev. 60(8), 915-928 (2008).
13. Scheerlinck J-PY, Greenwood DLV. Virus-sized vaccine delivery systems. Drug Discov. Today 13(19-20), 882-887 (2008).
14. Aguilar JC, Rodríguez EG. Vaccine adjuvants revisited. Vaccine 25(19), 3752-3762 (2007).
15. O'Hagan DT, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev. Vaccines 2, 269-283 (2003).
16. Schmidt CS, Morrow WJW, Sheikh NA. Smart adjuvants. Expert Rev. Vaccines 6, 391-400 (2007).
17. SayIn B, Somavarapu S, Li XW, Sesardic D, Senel S, Alpar OH. TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines. Eur. J. Pharm. Sci. 38(4), 362-369 (2009).
18. Gómez S, Gamazo C, San Roman B et al. A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne. J. Immunol. Methods 348(1-2), 1-8 (2009).
19. Gunaseelan S, Gunaseelan K, Deshmukh M, Zhang X, Sinko PJ. Surface modifcations of nanocarriers for effective intracellular delivery of anti-HIV drugs. Adv. Drug Deliv. Rev. 62(4-5), 518-531 (2010).
20. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol. 30(1), 23-32 (2009).
21. Jones KS. Biomaterials as vaccine adjuvants. Biotechnol. Progress 24(4), 807-814 (2008).
22. Mallapragada SK, Narasimhan B. Immunomodulatory biomaterials. Int. J. Pharm. 364(2), 265-271 (2008).
23. Thomas C, Gupta V, Ahsan F. Infuence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses. Int. J. Pharm. 379(1), 41-50 (2009).
24. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targeting of dendritic cells in lymph nodes with poly (propylene sulfde) nanoparticles. J. Controlled Release 112(1), 26-34 (2006).
25. Walter E, Dreher D, Kok M et al. Hydrophilic poly(D, L-lactide-co- glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells. J. Controlled Release 76 (1-2), 149-168 (2001).
26. Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, Ficht TA. Polymeric particles in vaccine delivery. Curr. Opin. Microbiol. 13(1), 106-112 (2009).
27. Thomasin C, Corradin G, Men Y, Merkle HP, Gander B. Tetanus toxoid and synthetic malaria antigen containing poly(lactide)/poly(lactide-co-glycolide) microspheres: importance of polymer degradation and antigen release for immune response. J. Controlled Release 41 (1-2), 131-145 (1996).
28. Slütter B, Soema PC, Ding Z, Verheul R, Hennink W, Jiskoot W. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen. J. Controlled Release 143(2), 207-214 (2010).
29. O'Hagan DT. Microparticles and polymers for the mucosal delivery of vaccines. Adv. Drug Deliv. Rev. 34(2-3), 305-320 (1998).
30. Kazzaz J, Neidleman J, Singh M, Ott G, O'Hagan DT. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J. Controlled Release 67(2-3), 347-356 (2000).
31. Jain S, Yap WT, Irvine DJ. Synthesis of protein-loaded hydrogel particles in an aqueous two-phase system for coincident antigen and CpG oligonucleotide delivery to antigen-presenting cells. Biomacromolecules 6(5), 2590-2600 (2005).
32. Shen Z, Reznikoff G, Dranoff G, Rock K. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J. Immunol. 158(6), 2723-2730 (1997).
33. Sharma S, Mukkur TKS, Benson HAE, Chen Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J. Pharm. Sci. 98(3), 812-843 (2009).
34. Katare YK, Muthukumaran T, Panda AK. Infuence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles. Int. J. Pharm. 301(1-2), 149-160 (2005).
35. Wendorf J, Singh M, Chesko J et al. A practical approach to the use of nanoparticles for vaccine delivery J. Pharm. Sci. 95(12), 2738-2750 (2006).
36. Gutierro I, Hernández RM, Igartua M, Gascón AR, Pedraz JL. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 21(1-2), 67-77 (2002).
37. Jung T, Kamm W, Breitenbach A, Hungerer K-D, Hundt E, Kissel T. Tetanus toxoid loaded nanoparticles from sulfobutylated poly (vinyl alcohol)-graft-poly (lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm. Res. 18(3), 352-360 (2001).
38. Vila A, Sanchez A, Evora C, Soriano I, Jato J, Alonso M. PEG-PLA nanoparticles as carriers for nasal vaccine delivery J. Aerosol Med. 17, 174-185 (2004).
39. Wendorf J, Chesko J, Kazzaz J et al. A comparison of anionic nanoparticles and microparticles as vaccine delivery systems. Hum. Vaccin. 4(1), 44-49 (2008).
40. Manocha M, Pal PC, Chitralekha KT et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine 23(48-49), 5599-5617 (2005).
41. Ying M, Gander B, Merkle HP, Corradin G. Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres. Vaccine 14(15), 1442-1450 (1996).
42. Panyam J, Labhasetwar V Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55(3), 329-347 (2003).
43. Elamanchili P, Diwan M, Cao M, Samuel J. Characterization of poly(D,L,-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22(19), 2406-2412 (2004).
44. Cui Z, Mumper RJ. Topical immunization using nanoengineered genetic vaccines. J. Controlled Release 81(1-2), 173-184 (2002).
45. Cui Z, Mumper RJ. Genetic Immunization Using nanoparticles engineered from microemulsion precursors. Pharm. Res. 19(7), 939-946 (2002).
46. Sloat BR, Sandoval MA, Hau AM, He Y, Cui Z. Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles. J. Controlled Release 141(1), 93-100 (2010).
47. Tobío M, Gref R, Sánchez A, Langer R, Alonso MJ. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm. Res. 15(2), 270-275 (1998).
48. Rieger J, Freichels H, Imberty A et al. Polyester nanoparticles presenting mannose residues: toward the development of new vaccine delivery systems combining biodegradability and targeting properties. Biomacromolecules 10(3), 651-657 (2009).
49. Andrianov AK, Marin A, Roberts BE. Polyphosphazene poly electrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity Biomacromolecules 6(3), 1375-1379 (2005).
50. Zwiorek K, Bourquin C, Battiany J et al. Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm. Res. 25(3), 551-562 (2008).
51. Coppi G, Iannuccelli V, Sala N, Bondi M. Alginate microparticles for polymyxin B Peyer's patches uptake: microparticles for antibiotic oral administration. J. Microencap. Micro Nano Carriers 21(8), 829-839 (2004).
52. Okada H, Toguchi H. Biodegradable microspheres in drug delivery Crit. Rev. Ther. Drug Carrier Syst. 12(1), 1-99 (1995).
53. Florindo HF, Pandit S, Lacerda L, Gonçalves LMD, Alpar HO, Almeida AJ. The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-[var s]-caprolactone-based nanoparticles. Biomaterials 30(5), 879-891 (2009).
54. Freitas S, Merkle HP, Gander B. Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology J. Controlled Release 102(2), 313-332 (2005).
55. Fifs T, Gamvrellis A, Crimeen-Irwin B et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 173(5), 3148-3154 (2004).
56. Sharp F, Ruane D, Claas B et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 infammasome. Proc. Natl Acad. Sci. USA 106, 870-875 (2009).
57. Kreuter J. Nanoparticles and microparticles for drug and vaccine delivery J. Anat. 189, 503-505 (1996). (Pubitemid 27011002)
58. Mumper RJ, Cui Z, Oyewumi MO. Nanotemplate engineering of cell specifc nanoparticles. J. Dispers. Sci. Technol. 24(3), 569-588 (2003).
59. Monfardini C, Veronese M. Stabilization of substances in circulation. Bioconjug. Chem. 9, 418-450 (1998).
60. Kim GJ, Nie S. Targeted cancer nanotherapy. Mater. Today 8(8 Suppl. 1), 28-33 (2005).
61. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res. 53(16), 3765-3770 (1993).
62. Xiang SD, Scholzen A, Minigo G et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods 40 (1), 1-9 (2006).
63. Kanchan V, Panda AK. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 28(35), 5344-5357 (2007).
64. Johansen P, Estevez F, Zurbriggen R et al. Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres. Vaccine 19(9-10), 1047-1054 (2000).
65. Johansen P, Gander B, Merkle HP, Sesardic D. Ambiguities in the preclinical quality assessment of microparticulate vaccines. Trends Biotechnol. 18(5), 203-211 (2000).
66. Caputo A, Brocca-Cofano E, Castaldello A et al. Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin. Vaccine 26(9), 1214-1227 (2008).
67. Mann JFS, Shakir E, Carter KC, Mullen AB, Alexander J, Ferro VA. Lipid vesicle size of an oral infuenza vaccine delivery vehicle infuences the Th1/Th2 bias in the immune response and protection against infection. Vaccine 27(27), 3643-3649 (2009).
68. Cruz LJ, Tacken PJ, Fokkink R et al. Targeted PLGA nano-but not microparticles specifcally deliver antigen to human dendritic cells via DC-SIGN in vitro. J. Controlled Release (2010) (In Press).
69. Newman KD, Elamanchili P, Kwon GS, Samuel J. Uptake of poly(D,L-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo J. Biomed. Mater. Res. 60(3), 480-486 (2002).
70. Tabata Y, Inoue Y, Ikada Y. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine 14(17-18), 1677-1685 (1996).
71. Panyam J, Labhasetwar V. Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm. Res. 20(2), 212-220 (2003).
72. Horisawa E, Kubota K, Tuboi I et al. Size-dependency of D,L-lactide/glycolide copolymer particulates for intra-articular delivery system on phagocytosis in rat synovium. Pharm. Res. 19(2), 132-139 (2002).
73. Doe B, Selby M, Barnett S, Baenziger J, Walker CM. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc. Natl Acad. Sci. USA 16, 8578-8583 (1996).
74. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kündig T, Hengartner H. Antigen localisation regulates immune responses in a dose-and time-dependent fashion: a geographical view of immune reactivity. Immunol. Rev. 156(1), 199-209 (1997).
75. Bramwell V W, Perrie Y. Particulate delivery systems for vaccines: what can we expect? J. Pharm. Pharmacol. 58, 717-728 (2006).
76. Brewer JM, Pollock KGJ, Tetley L, Russell DG. Vesicle size infuences the traffcking, processing, and presentation of antigens in lipid vesicles. J. Immunol. 173(10), 6143-6150 (2004).
77. Mottram PL, Leong D, Crimeen-Irwin B et al. Type 1 and 2 immunity following vaccination is infuenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol. Pharm. 4(1), 73-84 (2006).
78. Audran R, Peter K, Dannull J et al. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine 21(11-12), 1250-1255 (2003).
79. Balasse E, Odot J, Gatouillat G, Andry M-C, Madoulet C. Enhanced immune response induced by BSA loaded in hydroxyethylstarch microparticles. Int. J. Pharm. 353(1-2), 131-138 (2008).
80. Reddy ST, van der Vlies AJ, Simeoni E et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotech. 25(10), 1159-1164 (2007).
81. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann Martin F. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38(5), 1404-1413 (2008).
82. Mutwiri G, Benjamin P, Soita H, Babiuk LA. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen. Vaccine 26(22), 2680-2688 (2008).
83. Briones M, Singh M, Ugozzoli M et al. The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery. Pharm. Res. 18(5), 709-712 (2001). (Pubitemid 32595803)
84. O'Hagan D, Singh M, Ugozzoli M et al. Induction of potent immune responses by cationic microparticles with adsorbed human immunodefciency virus DNA vaccines. J. Virol. 75(19), 9037-9043 (2001).
85. Borges O, Borchard G, Verhoef JC, de Sousa A, Junginger HE. Preparation of coated nanoparticles for a new mucosal vaccine delivery system. Int. J. Pharm. 299(1-2), 155-166 (2005).
86. Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int. J. Pharm. 298(2), 315-322 (2005).
87. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6(2), 148-158 (2006).
88. Nakaoka R, Inoue Y, Tabata Y, Ikada Y Size effect on the antibody production induced by biodegradable microspheres containing antigen. Vaccine 14(13), 1251-1256 (1996).
89. Mohammed AR, Bramwell V W, Coombes AGA, Perrie Y. Lyophilisation and sterilisation of liposomal vaccines to produce stable and sterile products. Methods 40(1), 30-38 (2006).
90. Memisoglu-Bilensoy E, Hincal AA. Sterile, injectable cyclodextrin nanoparticles: Effects of g irradiation and autoclaving. Int. J. Pharm. 311(1-2), 203-208 (2006).
91. Konan YN, Cerny R, Favet J, Berton M, Gurny R, Allémann E. Preparation and characterization of sterile sub-200 nm meso-tetra(4- hydroxylphenyl)porphyrin-loaded nanoparticles for photodynamic therapy. Eur. J. Pharm. Biopharm. 55(1), 115-124 (2003).
92. Konan YN, Gurny R, Allémann E. Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int. J. Pharm. 233(1-2), 239-252 (2002).
93. Masson V, Maurin F, Fessi H, Devissaguet JP. Infuence of sterilization processes on poly([var e]-caprolactone) nanospheres. Biomaterials 18(4), 327-335 (1997).
94. Sintzel MB, Merkli A, Tabatabay C, Gurny R. Infuence of irradiation sterilization on polymers used as drug carriers: a review. Drug Develop. Industrial Pharm. 23(9), 857-878 (1997).
95. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 47(2-3), 165-196 (2001).
96. Rollot JM, Couvreur P, Roblot-Treupel L, Puisieux F. Physicochemical and morphological characterization of polyisobutyl cyanoacrylate nanocapsules. J. Pharm. Sci. 75(4), 361-364 (1986).
97. Bozdag S, Dillen K, Vandervoort J, Ludwig A. The effect of freeze-drying with different cryoprotectants and g-irradiation sterilization on the characteristics of ciprofoxacin HCl-loaded poly(D,L-lactide-glycolide) nanoparticles. J. Pharm. Pharmacol. 57, 699-708 (2005).
98. Quintanar-Guerrero D, Ganem-Quintanar A, Allemann E, Fessi H, Doelker E. Infuence of the stabilizer coating layer on the purifcation and freeze-drying of poly(D,L-lactic acid) nanoparticles prepared by an emulsion-diffusion technique. J. Microencapsul. 15(1), 107-119 (1998).
99. Glavas-Dodov M, Fredro-Kumbaradzi E, Goracinova K et al. The effects of lyophilization on the stability of liposomes containing 5-FU. Int. J. Pharm. 291(1-2), 79-86 (2005).
100. Chen D, Kristensen D. Opportunities and challenges of developing thermostable vaccines. Expert Rev. Vaccines 8, 547-557 (2009).
101. Sloat BS, Sandoval MA, Cui Z. Towards preserving the immunogenicity of protein antigens carried by nanoparticles while avoiding the cold chain. Int. J. Pharm. 393(1-2), 197-202 (2010).
102. Nixon DF, Hioe C, Chen P-D et al. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 14(16), 1523-1530 (1996).
103. Nagamoto T, Hattori Y, Takayama K, Maitani Y. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm. Res. 21(4), 671-674 (2004).
104. Igartua M, Hernández RM, Esquisabel A, Gascón AR, Calvo MB, Pedraz JL. Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres. J. Controlled Release 56(1-3), 63-73 (1998).